QIAGEN Price to Free Cash Flow Ratio 2010-2022 | QGEN

Historical price to free cash flow ratio values for QIAGEN (QGEN) since 2010. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
QIAGEN Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2023-02-07 49.80 17.62
2022-09-30 41.28 $2.83 14.61
2022-06-30 47.20 $2.48 19.05
2022-03-31 49.00 $2.35 20.88
2021-12-31 55.58 $1.94 28.72
2021-09-30 51.68 $2.26 22.86
2021-06-30 48.38 $1.80 26.89
2021-03-31 48.69 $1.76 27.63
2020-12-31 52.85 $1.39 38.08
2020-09-30 52.26 $0.77 67.64
2020-06-30 42.81 $1.05 40.59
2020-03-31 41.60 $0.83 50.13
2019-12-31 33.80 $0.94 36.00
2019-09-30 32.97 $0.91 36.06
2019-06-30 40.55 $0.86 47.42
2019-03-31 40.68 $1.03 39.31
2018-12-31 34.45 $1.07 32.21
2018-09-30 37.88 $0.97 39.15
2018-06-30 36.16 $0.98 36.97
2018-03-31 32.31 $0.78 41.31
2017-12-31 30.93 $0.84 36.63
2017-09-30 31.50 $0.97 32.63
2017-06-30 33.53 $1.06 31.65
2017-03-31 28.97 $1.18 24.58
2016-12-31 29.10 $1.12 26.03
2016-09-30 28.50 $0.99 28.87
2016-06-30 22.65 $1.00 22.54
2016-03-31 23.20 $0.87 26.53
2015-12-31 28.71 $0.92 31.17
2015-09-30 26.81 $0.90 29.64
2015-06-30 25.74 $0.87 29.69
2015-03-31 26.17 $0.88 29.65
2014-12-31 24.36 $0.83 29.37
2014-09-30 23.65 $0.87 27.19
2014-06-30 25.39 $0.81 31.25
2014-03-31 21.90 $0.74 29.61
2013-12-31 24.73 $0.75 33.04
2013-09-30 22.22 $0.68 32.84
2013-06-30 20.68 $0.63 32.62
2013-03-31 21.89 $0.78 27.95
2012-12-31 18.85 $0.62 30.30
2012-09-30 19.22 $0.68 28.48
2012-06-30 17.34 $0.66 26.34
2012-03-31 16.17 $0.54 30.14
2011-12-31 14.34 $0.70 20.63
2011-09-30 14.36 $0.76 18.79
2011-06-30 19.75 $1.05 18.83
2011-03-31 20.82 $0.83 25.23
2010-12-31 20.30 $0.76 26.81
2010-09-30 18.42 $0.55 33.32
2010-06-30 19.96 $0.71 27.96
2010-03-31 23.87 $0.75 31.70
2009-12-31 23.19 $0.71 32.49
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $11.308B $2.142B
QIAGEN N.V. is one of the world's leading providers of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA. The company provides innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. It has developed a comprehensive portfolio of proprietary, consumable products, and automated solutions for sample collection. Qiagen has subsidiaries several other countries with good sales potential. Segment Details Consumables: These are typically sample preparation or test kits that contain all the necessary reagents and buffers, and a manual including protocols and relevant background information. Automated Instruments: These automate the use of Sample & Assay Technologies into efficient solutions for a broad range of laboratory needs. Customer Classes: QIAGEN focuses on 4 principal segments or customer classes for sample and assay technologies:? Molecular Diagnostics, Applied Testing, Pharma and Academia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $158.441B 9.68
GSK (GSK) United Kingdom $74.044B 9.78
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
Ginkgo Bioworks Holdings (DNA) United States $3.880B 0.00
Myovant Sciences (MYOV) United Kingdom $2.617B 0.00
Arcus Biosciences (RCUS) United States $1.545B 23.20
Biohaven (BHVN) United States $1.265B 0.00
Emergent Biosolutions (EBS) United States $0.703B 5.53
ADC Therapeutics SA (ADCT) Switzerland $0.348B 0.00
Enzo Biochem (ENZ) United States $0.068B 0.00
Ambrx Biopharma (AMAM) United States $0.066B 0.00
Gelesis Holdings (GLS) United States $0.025B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00